REVIEW article

Front. Surg., 28 June 2022

Sec. Surgical Oncology

Volume 9 - 2022 | https://doi.org/10.3389/fsurg.2022.895976

Robotic Versus Laparoscopic Gastrectomy for Gastric Cancer: A Mega Meta-Analysis

  • 1. Clinical Medical College, Yangzhou University, YangzhouChina

  • 2. Department of Gastrointestinal Surgery, Northern Jiangsu People’s Hospital, YangzhouChina

  • 3. General Surgery Institute of Yangzhou, Yangzhou University, YangzhouChina

  • 4. Yangzhou Key Laboratory of Basic and Clinical Transformation of Digestive and Metabolic Diseases, Yangzhou China

Abstract

Background:

Laparoscopic gastrectomy and robotic gastrectomy are the most widely adopted treatment of choice for gastric cancer. To systematically assess the safety and effectiveness of robotic gastrectomy for gastric cancer, we carried out a systematic review and meta-analysis on short-term and long-term outcomes of robotic gastrectomy.

Methods:

In order to find relevant studies on the efficacy and safety of robotic gastrectomy (RG) and laparoscopic gastrectomy (LG) in the treatment of gastric cancer, numerous medical databases including PubMed, Medline, Cochrane Library, Embase, Google Scholar, and China Journal Full-text Database (CNKI) were consulted, and Chinese and English studies on the efficacy and safety of RG and LG in the treatment of gastric cancer published from 2012 to 2022 were screened according to inclusion and exclusion criteria, and a meta-analysis was conducted using RevMan 5.4 software.

Results:

The meta-analysis inlcuded 48 literatures, with 20,151 gastric cancer patients, including 6,175 in the RG group and 13,976 in the LG group, respectively. Results of our meta-analysis showed that RG group had prololonged operative time (WMD = 35.72, 95% CI = 28.59–42.86, P < 0.05) (RG: mean ± SD = 258.69 min ± 32.98; LG: mean ± SD = 221.85 min ± 31.18), reduced blood loss (WMD = −21.93, 95% CI = −28.94 to −14.91, P < 0.05) (RG: mean ± SD = 105.22 ml ± 62.79; LG: mean ± SD = 127.34 ml ± 79.62), higher number of harvested lymph nodes (WMD = 2.81, 95% CI = 1.99–3.63, P < 0.05) (RG: mean ± SD = 35.88 ± 4.14; LG: mean ± SD = 32.73 ± 4.67), time to first postoperative food intake shortened (WMD = −0.20, 95% CI = −0.29 to −0.10, P < 0.05) (RG: mean ± SD = 4.5 d ± 1.94; LG: mean ± SD = 4.7 d ± 1.54), and lower length of postoperative hospital stay (WMD = −0.54, 95% CI = −0.83 to −0.24, P < 0.05) (RG: mean ± SD = 8.91 d ± 6.13; LG: mean ± SD = 9.61 d ± 7.74) in comparison to the LG group. While the other variables, for example, time to first postoperative flatus, postoperative complications, proximal and distal mar gin, R0 resection rate, mortality rate, conversion rate, and 3-year overall survival rate were all found to be statistically similar at P > 0.05.

Conclusions:

In the treatment of gastric cancer, robotic gastrectomy is a safe and effective procedure that has both short- and long-term effects. To properly evaluate the advantages of robotic surgery in gastric cancer, more randomised controlled studies with rigorous research methodologies are needed.

Introduction

Gastric cancer is the most common malignant tumor of the digestive tract in far-eastern countries. The global incidence of gastric cancer has declined steadily in recent years, but Asia still has the highest incidence of gastric cancer (). Due to the lack of early diagnosis methods, most patients are already in the middle and late stages of the disease at the time of their diagnosis. The best method of treatment is currently surgery. The surgical method has evolved from traditional open surgery to laparoscopic surgery (). Since the mid-1980s, laparoscopic techniques have received increasing recognition for their minimally invasive advantages in treating gastric cancer (), and laparoscopic gastrectomy (LG) has become the standard treatment for early gastric cancer. Nonetheless, laparoscopic techniques have some limitations and shortcomings, including inflexible operation of surgical instruments, two-dimensional imaging display interface, and a limited range of operation. In recent years, robotic technologies have made tremendous progress in overcoming the technological limitations of traditional laparoscopy. Robot-assisted surgical procedure has visual direction from the bottom to the top and not the other way around as in traditional open surgery, which makes it more advantageous to expose the dirty surface tissue. Although several scholars have conducted meta-analyses of such studies, all of them focused on assessing its immediate efficacy without considering its long-term effectiveness, such as its 3-year survival rate, and some of the results differed from study to study. As the robotic surgery system continues to advance, both its technology and efficacy are continually improving, and the research reports associated with it continue to be updated. In addition, the robotic system was only recently applied to some patients undergoing gastric cancer surgery, and its status in the treatment of gastric cancer has not been conclusively established or included in guidelines. To evaluate the short and long-term efficacy and safety of the robotic surgery system in the clinical treatment of gastric cancer, this study conducted a meta-analysis of published clinical comparative studies (–) on RG and LG.

Materials & Methods

Search Strategy

In order to search PubMed, Medline, Cochrane Library, Embase, Google Scholar, and China Journal Full-text Database (CNKI) and other databases according to clinical comparison studies of RG and LG, the search strings “Robotic OR da Vinci OR Robot-Assisted”, “Gastrectomy”, “Gastric “, “Cancer OR Carcinoma OR Tumor OR Neoplasm”, “Laparoscopic OR Laparoscopic-Assisted “ and “Robotic”, Searches were limited to the period 2012–2021, with the “related search” feature being utilized further to exclude omissions.

Literature Inclusion and Exclusion Criteria

Inclusion criteria: (1) published randomized or non-randomized controlled trials comparing RG with LG; (2) patients diagnosed with gastric cancer who have undergone their first surgical procedure; (3) provide clear criteria for the selection of study cases and methods for grouping; (4) provide evidence of clinical efficacy comparison between RG and LG; (5) include data studies of superior quality and detail; (6) describe the raw data, including continuous variables such as mean and standard deviation, and count information such as the number of events and the number of samples. For dichotomous variables, the combined odds ratio (OR) and 95% confidence interval (CI) should be provided, as well as a regression coefficient that can be converted to the combined OR and 95% CI and standard error. Exclusion criteria: (1) comparisons of non-LG and RG cases; (2) study cases containing other benign gastrointestinal diseases; (3) study cases having only undergone palliative major gastrectomy, tumor reduction, or short-circuit surgery; (4) study cases involving emergency surgery; (5) no reliable comparisons could be drawn from the literature; (6) duplicate published studies; (7) no controlled studies conducted simultaneously; and (8) no clear grouping tendency in terms of the extent of lymph node dissection or stage of the disease.

Data Extraction

Extractions are made by two investigators independently, and if a dispute occurs, it is resolved through mutual discussion or by a third party. The following data types can be identified: (1) General information, including the names of the authors, the dates of literature publication, the type of study, the sample size, the tumor site and its size, and the TNM stage; (2) outcome indicators, such as operative time and blood loss, lymph node dissection, transit rate, distal margin length, R0 resection rate, postoperative hospital stay, immediate postoperative gas and food intake, complication rate, 3-year survival rate, and morbidity and mortality rate.

Evaluation of the Quality of the Literature

We used the MINORS scoring criteria () to assess the quality of the clinical trials (score 0: no description, score 1: inadequate description, and score 2: adequate description). A modified set of MINORS scoring criteria containing 12 items, which yields scores ranging from 0 to 24 was used to evaluate the quality of the literature included in this study (Supplementary file Appendix 1).

Statistical Analysis

We performed the meta-analysis using RevMan 5.4 software, using odds ratio (OR) values for measurement data and weighted mean differences (WMD) for efficacy analysis for count data. The 95% confidence interval (CI) for the effect sizes was calculated. It was checked for heterogeneity between the studies using the χ2 test and I2 values, and in case of heterogeneity (I2 > 50%, P < 0.05), a random-effects model was applied; if there was no heterogeneity (I2< 50%, P≥ 0.05), a fixed-effects model was applied. The differences were considered statistically significant at P < 0.05.

Results

Search Results

A preliminary search retrieved a total of 5,440 articles published from 2012 to 2021. After reviewing all titles and abstracts, 76 complete articles were found, 28 of which were rejected because they did not meet the inclusion criterion. Supplementary Figure 1 illustrates the search process. Ultimately, 20,151 patients data from 48 retrospective studies were included in the present study, with 6,175 in the RG group and 13,976 in the LG group (–). Table 1 presents the basic characteristics of the included literature and MINORS scale for quality assessment, while Table 2 provides the patients' characteristics of the included literature. Supplementary Figure 2 depicts MINORS scores bar graph for the observational studies included in our systematic review.

Table 1

AuthorYearCountryStudy periodStudy designSample size
Surgical extensionLevel of LNDMINORS
RGLG
Eom ()2012Korea2009–2010OCS (P)3062DD1, D222
Kang ()2012Korea2008–2011OCS (P)100282D, TD1, D222
Yoon ()2012Korea2009–2011OCS (R)3665TD1, D223
Uyama ()2012Japan2009–2010OCS (P)25225DD221
Kim KM ()2012Korea2005–2010OCS (P)436861D, TD1, D223
Huang ()2012Taiwan2006–2012OCS (R)3964D, P, TD1, D222
Zhang XL ()2012China2009–2011OCS (P)9770D, P, TD218
Hyun ()2013Korea2009–2010OCS (P)3883D, TD1, D222
Kim HI ()2014Korea2003–2009OCS (P)172481D, TD1, D222
Noshiro ()2014Japan2010–2012OCS (P)21160DD1, D222
Huang ()2014Taiwan2008–2014OCS (P)7273D, TD1, D222
Son T ()2014Korea2003–2010OCS (P)5158TD222
Zhou ()2014China2010–2013OCS (R)120394D, P, TD1, D223
Liu J ()2014China2012–2013OCS (R)100100D, P, TD219
Han ()2015Korea2008–2013OCS (R)6868PPGD123
Seo ()2015Korea2004–2009OCS (P)4040DD1, D220
Park ()2015Korea2009–2011OCS (P)145612D, TD119
Lee ()2015Korea2003–2010OCS (P)133267DD221
Suda ()2015Japan2009–2012OCS (R)88438D, TD1, D222
Shen ()2015China2011–2014OCS (R)93330D, TD1, D221
Li P ()2015China2011–2014OCS (R)126124TD221
Cianchi ()2016Italy2008–2015OCS (P)3041DD1, D221
Kim HI ()2016Korea2011–2012OCS (P)185185D, TD1, D223
Nakauchi ()2016Japan2009–2012OCS (R)84437D, TD1, D223
Hong ()2016Korea2008–2015OCS (P)232232DD1, D222
Kim YW ()2016Korea2009–2011OCS (P)87288DD1, D220
Xue ()2016China2012–2014OCS (R)3535DD220
Parisi ()2017Italy2015–2016OCS (P)151151D, TD221
Yang ()2017Korea2009–2015OCS (P)173511D, TD1, D221
Li GT ()2017China2017OCS (R)1515TD220
Teng ()2017China2016–2017OCS (R)4158DD1, D220
Hu ()2017China2014–2016OCS (R)3939DD221
Lan ()2017China2014–2016OCS (R)196673D, P, TNA20
Liu HB ()2018China2017OCS (R)100135D, TD1, D221
Lu ()2018China2016–2017OCS (P)101303D, TD1, D220
Obama ()2018Korea2005–2009OCS (P)315525D, TD1, D223
Zhang K ()2018China2011–2013OCS (R)2762D, P, TD123
Li ZY ()2018China2013–2017OCS (P)112112D, TD223
Li SY ()2018China2015–2017OCS (R)5056DD221
Wang WJ ()2019China2016–2018OCS (P)251276D, TD223
Gao ()2019China2011–2014OCS (P)163339D, P, TD1, D221
Alhossaini ()2020Korea2015–2017OCS (R)2530TNA23
Ye SP ()2020China2014–2019OCS (P)285285DD223
Shibasaki ()2020Japan2009–2019OCS (P)3591042D, P, TD1, D222
Kong ()2020China2014–2017OCS (R)294750D, P, TD1, D223
Shin ()2021Japan2009–2017OCS (P)4211663D, T, PPGD1, D223
Hikage ()2021Japan2012–2020OCS (P)345835D, P, TD1, D223
Li ZY (51)2021China2006–2019OCS (P)2941D, P, TNA23

Basic characteristics of the literatures included in the meta-analysis.

NA, not available; OCS, observational clinical study; P, prospectively collected data; R, retrospectively collected data; D, distal gastrectomy; P, proximal gastrectomy; T, total gastrectomy; PPG, pylorus-preserving gastrectomy.

Table 2

AuthorYearGender (M/F)
Age
BMI (kg/m2)
TNM Stage
RGLGRGLGRGLG
Eom ()201221/941/2152.8 ± 11.557.9 ± 1124.2 ± 4.524.1 ± 2.7I, II, III
Kang ()201263/37191/9153.2 ± 12.0358.78 ± 12.4023.74 ± 3.7223.63 ± 3.47I, II, III
Yoon ()201218/1831/3453.9 ± 11.756.9 ± 12.323.2 ± 2.523.6 ± 3.4T1∼3N0∼2
Uyama ()201214/11156/6961.6 ± 11.062.6 ± 9.922.6 ± 3.122.0 ± 3.1T1N0
Kim KM ()2012265/171550/31154.2 ± 12.558.8 ± 12.023.6 ± 3.123.5 ± 2.8T0∼4N0∼3
Huang ()201219/2043/2165.1 ± 15.965.6 ± 14.824.2 ± 3.724.7 ± 3.3I, II, III
Zhang XL ()201266/3149/2156.1 ± 5.854.8 ± 4.922.5 ± 3.621.7 ± 2.1I, II, III
Hyun ()201325/1355/2854.2 ± 12.760.3 ± 12.323.8 ± 2.623.8 ± 2.9I, II, III
Kim HI ()2014103/69294/18755.2 13.061.3 ± 11.923.7 ± 2.923.6 ± 2.9I, II, III
Noshiro ()201414/7102/5866 ± 1069 ± 1222.8 ± 3.121.8 ± 2.8I, II, III, IV
Huang ()201440/3242/3167.7 ± 15.166.0 ± 13.524.1 ± 3.324.2 ± 3.3I, II, III
Son T ()201423/2836/2255.3 ± 12.258.8 ± 12.222.7 ± 2.923.2 ± 3.3I, II, III
Zhou ()201490/30276/11854.7 ± 10.155.6 ± 11.821.6 ± 2.821.7 ± 2.6I, II, III
Liu J ()201459/4163/3766.4 ± 5.767.8 ± 4.822.4 ± 1.823.1 ± 1.2I, II, III, IV
Han ()201531/3732/3650.6 ± 8.349.8 ± 11.522.7 ± 2.422.8 ± 3.0I, II, III
Seo ()201519/2120/2051.6 ± 4.555.1 ± 5.123.6 ± 2.123.8 ± 1.9I, II, III
Park ()201577/71369/25354.5 ± 11.658.3 ± 11.823.9 ± 3.323.9 ± 3.0I, II, III
Lee ()201585/48154/11353.6 ± 13.259.2 ± 11.723.2 ± 2.723.7 ± 2.8I, II, III
Suda ()201551/37307/13164 ± 1368 ± 13.522.6 ± 3.921.8 ± 7.9I, II, III, IV
Shen ()201575/18249/8156.8 ± 10.557.9 ± 11.524.3 ± 3.323.8 ± 3.6I, II, III
Li P ()201570/5664/6056.7 ± 9.957 ± 10.621.4 ± 3.822.2 ± 3.7NA
Cianchi ()201614/1619/2273 ± 10.274 ± 11.727 ± 3.726 ± 1.7I, II, III
Kim HI ()2016113/72113/7253.3 ± 11.456.0 ± 11.523.8 ± 3.023.6 ± 2.7I, II, III
Nakauchi ()201648/36307/13064 ± 1368 ± 13.522.6 ± 3.921.8 ± 5.2NA
Hong ()2016154/78156/7653.7 ± 11.555 ± 13.023.8 ± 3.323.8 ± 3.0T1∼4N0∼3
Kim YW ()201646/41170/11854.1 ± 12.060.5 ± 11.024.1 ± 3.424.0 ± 4.3I, II, III
Xue ()201626/925/1059.2 ± 9.656.2 ± 14.124.6 ± 2.923.4 ± 2.3I, II, III
Parisi ()201781/7085/6668.81 ± 12.1265.82 ± 14.1624.58 ± 3.0024.02 ± 2.22I, II, III
Yang ()201798/75258/253NANA23.6 ± 3.223.7 ± 3.1I, II, III
Li GT ()201714/110/558.73 ± 9.7955.07 ± 14.0722.42 ± 2.7321.92 ± 3.39I, II, III
Teng ()201729/1240/1858 ± 11.259 ± 9.824.25 ± 2.0124.64 ± 2.80I, II, III, IV
Hu ()201728/1120/1959. 41 ± 12. 3456. 72 ± 12. 47NANAI, II, III
Lan ()2017137/59501/17259 ± 11.659 ± 11.623.6 ± 4.623.5 ± 4.5T0∼4N0∼3
Liu HB ()201879/21101/3458 ± 4.458 ± 3.721.2 ± 0.922 ± 1.0I, II, III, IV
Lu ()201873/28212/91NANANANAI, II, III
Obama ()2018189/126327/19854.5 ± 12.659.3 ± 11.923.6 ± 3.123.5 ± 2.9I, II, III
Zhang K ()201819/852/1059.7 + 11.656.6 + 12.224.9 + 2.724.5 + 3.2I, II, III
Li ZY ()201878/3479/3355.6 ± 11.356.1 ± 11.123.6 ± 2.923.6 ± 3.0I, II, III
Li SY ()201835/1539/1765.6 ± 8.366 ± 7.424.3 ± 2.124.6 ± 2.4T2, T3, T4a
Wang WJ ()2019201/50205/7157.7 ± 11.256.8 ± 11.522.1 ± 3.522.4 ± 3.4I, II, III
Gao ()2019121/42201/13860.27 ± 10.5059.36 ± 11.0823.77 ± 3.1123.44 ± 3.47I, II, III
Alhossaini ()202017/822/854 ± 1560 ± 1522.5 ± 2.722.2 ± 2.9I, II, III, IV
Ye SP ()2020189/96186/9957.1 ± 8.357.0 ± 8.624.4 ± 2.324.5 ± 2.2I, II, III
Shibasaki ()2020233/126740/30267 ± 14.770 ± 17.222.8 ± 4.422.4 ± 5.6I, II, III
Kong ()2020221/73536/21458.57 ± 10.5159.10 ± 10.2022.9 ± 4.422.2 ± 5.7I, II, III
Shin ()2021264/1571088/57553 ± 1260 ± 1223.87 ± 3.1323.89 ± 3.22I, II, III
Hikage ()2021219/126595/24067 ± 1669 ± 16.522.3 ± 4.0522.7 ± 5.5I, II, III
Li ZY (51)202122/731/1060.3 ± 12.658.2 ± 9.819.4 ± 2.220.4 ± 2.5I, II, III

Patients’ characteristics of the included literature.

NA, not available; M male; F, female; RG, robotic gastrectomy; LG, laparoscopic gastrectomy.

Table 3

OutcomesNo. of studiesSample size
Heterogeneity
Overall effect size95% CI of overall effectP value
RGLGI2 (%)P value
Operation time (min)45590013,19997<0.05WMD = 35.7228.59–42.86<0.05
Intraoperative blood loss (mL)43590513,45193<0.05WMD = −21.93−28.94 to −14.91<0.05
Lymph node dissection46593013,08287<0.05WMD = 2.811.99–3.63<0.05
Time to first flatus (days)263084532297>0.05WMD = −0.20−0.42 to 0.02>0.05
Time to first food intake (days)263855716053<0.05WMD = −0.20−0.29 to −0.10<0.05
Length of hospital stay (days)46613613,91280<0.05WMD = −0.54−0.83 to −0.24<0.05
Postoperative complications47613613,93722>0.05OR = 0.880.78–1.00>0.05
Proximal margin (cm)162176487857>0.05WMD = −0.02−0.23 to 0.19>0.05
Distal margin (cm)162125482071>0.05WMD = 0.18−0.71 to 0.48>0.05
R0 resection rate5617513,9760>0.05OR = 1.740.70–4.28>0.05
Tumor size (cm)223176729595>0.05WMD = −0.19−0.52 to 0.14>0.05
Mortality rate20423998230>0.05OR = 1.160.76–1.76>0.05
Conversion rate14361497730>0.05OR = 0.640.40–1.00>0.05
Reoperation rate13219246930>0.05OR = 1.050.68–1.62>0.05
Overall survival121926485788>0.05OR = 1.190.70–2.00>0.05

Overall results of the meta-analysis.

Meta-Analysis Results

Operation time was reported in 45 publications, with homogeneity test I2 = 97%, P < 0.05. Using a random effect model analysis showed that the RG group had a significantly longer operation time than the LG group (WMD = 35.72, 95% CI = 28.59–42.86, P < 0.05) (Figure 1). The mean ± SD values are 258.69 min ± 32.98 and 221.85 min ± 31.18, for the RG and LG groups, respectively.

Figure 1

Intraoperative bleeding was reported in 43 publications with homogeneity test I2 = 93%, P < 0.05, and analysis using a random effects model showed that intraoperative bleeding was significantly less in the RG group than in the LG group (WMD = −21.93, 95% CI = −28.94 to −14.91, P < 0.05) (Figure 2). The mean ± SD values are 105.22 ml ± 62.79 and 127.34 ml ± 79.62, for the RG and LG groups, respectively.

Figure 2

Number of lymph node dissection 46 publications reported the number of lymph node dissections with homogeneity test I2 = 87%, P < 0.05, and analysis using a random effects model showed that the number of lymph node dissections was higher in the RG group than in the LG group (WMD = 2.81, 95% CI = 1.99–3.63, P < 0.05) using random effects model analysis (Figure 3). The mean ± SD values are 35.88 ± 4.14 and 32.73 ± 4.67, for the RG and LG groups, respectively.

Figure 3

Time to first postoperative flatus 26 publications reported time to first postoperative flatus with homogeneity test I2 = 97%, P < 0.05, and analysis using a random effects model showed not statistically significant in time to first postoperative flatus between the two groups (WMD = −0.20, 95% CI = −0.42 to 0.02, P > 0.05) (Figure 4). The mean ± SD values are 5.02 d ± 1.24 and 5.25 d ± 2.54, for the RG and LG groups, respectively.

Figure 4

Time to first postoperative food intake 26 publications reported time to first postoperative food intake with homogeneity test I2 = 53%, P < 0.05, and analysis using a random effects model showed that time to first postoperative food intake was significantly shorter in the RG group than in the LG group (WMD = −0.20, 95% CI = −0.29 to −0.10, P < 0.05) (Figure 5). The mean ± SD values are 4.55 d ± 1.94 and 4.76 d ± 1.54, for the RG and LG groups, respectively.

Figure 5

Postoperative length of hospital stays 46 publications reported postoperative length of stay, homogeneity test I2 = 80%, P < 0.05, and a random effects model analysis showed significantly lower length of hospital stay in the RG group than in the LG group (WMD = −0.54, 95% CI = −0.83 to −0.24, P < 0.05) (Figure 6). The mean ± SD values are 8.91 d ± 6.13 and 9.61 d ± 7.74, for the RG and LG groups, respectively.

Figure 6

Postoperative Complication rates 47 publications reported complication rates with homogeneity test I2 = 22%, P > 0.05, and a random effects model analysis showed no statistically significant difference in complication rates between the two groups (OR = 0.88, 95% CI = 0.78–1.00, P < 0.05) (Figure 7). The average complication rate was 15.68 in RG group and 39.89 in LG group.

Figure 7

Proximal margin distance 16 publications reported proximal margin distance with homogeneity test I2 = 57%, P < 0.05, and analysis using a random effects model analysis showed no statistically significant difference in proximal margin distance between the two groups (WMD = −0.02, 95% CI = −0.23 to 0.19, P > 0.05) (Supplementary Figure 3). The mean ± SD values are 4.05 cm ± 1.15 and 4.05 cm ± 0.94, for the RG and LG groups, respectively.

Distal margin distance 16 publications reported distal margin distance with homogeneity test I2 = 71%, P < 0.05, and a random effects model analysis showed not statistically significant in distal margin distance between the two groups (WMD = 0.18, 95% CI = −0.71 to 0.48, P > 0.05) (Supplementary Figure 4). The mean ± SD values are 5.98 cm ± 1.56 and 5.66 cm ± 1.89, for the RG and LG groups, respectively.

R0 resection rates 48 publications reported R0 resection rates with homogeneity test I2 = 0%, P > 0.05, and analysis using a fixed effect model showed no statistically significant difference in R0 resection rates between the two groups (OR = 1.74, 95% CI = 0.70–4.28, P > 0.05) (Supplementary Figure 5). The average R0 resection rate was 128.52 in RG group and 290.81 in LG group.

Tumor size 22 publications reported tumor size with homogeneity test I2 = 95%, P < 0.05, and analysis using a random effects model analysis showed no statistically significant difference in tumor size between the two groups (WMD = −0.19, 95% CI = −0.52 to 0.14, P > 0.05) (Supplementary Figure 6). The mean ± SD values are 3.27 cm ± 0.82 and 3.31 cm ± 0.76, for the RG and LG groups, respectively.

Mortality rate 20 publications reported mortality rate with homogeneity test I2 = 0%, P > 0.05, and analysis using a fixed effect model showed no statistically significant difference in mortality rate between the two groups (OR = 1.16, 95% CI = 0.76–1.76, P > 0.05) (Supplementary Figure 7). The average mortality rate was 1.32 in RG group and 3 in LG group.

Conversion rate 14 publications reported conversion rate with homogeneity test I2 = 0%, P > 0.05, and a fixed effect model analysis showed no statistically significant difference in conversion rate between the two groups (OR = 0.64, 95% CI = 0.40–1.00, P > 0.05) (Supplementary Figure 8). The average conversion rate was 0.88 in RG group and 3.03 in LG group.

Reoperation rate 13 publications reported reoperation rate with homogeneity test I2 = 0%, P > 0.05, and a fixed effect model analysis showed no statistically significant difference in reoperation rate between the two groups (OR = 1.05, 95% CI = 0.68–1.62, P > 0.05) (Figure 8). The average reoperation rate was 2.14 in RG group and 4.28 in LG group.

Figure 8

Overall survival 12 publications reported 3-year survival rates with homogeneity test I2 = 88%, P < 0.05, and a random effects model analysis showed no statistically significant difference in 3-year survival between the two groups (OR = 1.19, 95% CI = 0.70–2.00, P > 0.05) (Figure 9). The average overall survival was 137.91 in RG group and 321.16 in LG group.

Figure 9

Heterogeneity and Sensitivity Analysis

Heterogeneity is considered to be significant when I2 > 50% and P < 0.05. Our results suggest that there was heterogeneity in the time to first flatus, proximal margin, distal margin, tumor size, and overall survival (I2 > 50%, P > 0.05) (Table 3). Furthermore, substantial heterogeneity was also in operation time, intraoperative bleeding loss, lymph node dissection, and time to first food intake (I2 > 50%, P < 0.05) (Table 3). According to the MINORS score, high-quality literature with a score of more than 18 points was selected for sensitivity analysis.

Publication of Bias

Evaluation of publication bias was accomplished using a funnel plot of intraoperative blood loss, lymph node dissection, and postoperative complications. There was no evidence of publication bias in the bilaterally symmetrical funnel plots of overall complications (Supplementary Figures 9, 10, 11).

Discussion

In most cases of gastric cancer, gastrostomies are the mainstay of treatment. Almost thirty years ago, minimally invasive gastrostomies were introduced to reduce patient burden. As a result of the increasing availability of surgical robots, a robotic-assisted gastrectomy was performed for the first time in Japan in 2002 (52). Currently, robotic surgery is widely used in general surgery as well as other applications (). In comparison to laparoscopic gastrectomy (LG), the feasibility and safety of the robotic-assisted (RG) technique were explored in this study.

Robotic surgery has become increasingly popular in a variety of surgeries due to its increased surgical precision and safety. Since the earliest application of robotics in surgery, it has evolved in five distinct categories: endoscopic, stereotactic, bioinspired, millimeter-scale microbots, and autonomous systems. Robotic surgery has shown to have dramatically superior clinical results when compared to laprascopic and open surgical techniques. In our study, of the 48 publications examined, 38 researches employed the Da Vinci surgical systems while the other 10 did not specify the surgical systems used (supplementary Figure 12.) According to the results of the comparative analysis of RG and LG gastric cancer treatment found in this study, there are disparities in efficacy between these treatments.

Based on the meta-analysis, it was found that RG requires a longer surgical procedure time than LG. One of the main reasons is that the robotic surgical system necessitates machine assembly at the beginning of the operation, and Jiménez-Rodrguez et al. (53) reported that the average preparation time for RG was 62.9% ± 24.6%min, but with experience the preparation time gradually decreases. Huang et al. () reported that the preparation time could be reduced to thirty minutes after 25 surgical operations. A study by Kang et al. () reported that the experienced RG group had a considerably shorter mean operation time than the inexperienced RG group. Furthermore, robotic surgery is a relatively new minimally invasive procedure that necessitates a learning process to master which is significantly shorter than LG. As reported by Mege et al. (54) and Huang et al. (), the learning curve for LG surgery ranges from 30 to 50 cases, whereas surgeons performing 10–20 RG cases would accomplish a stable level of operative time. Huang et al. () compared LG to RG in the middle and later stages of the learning curve, finding LG to have a longer operative time than RG regardless of the stage. Consequently, once the learning curve is passed, the time spent intraoperatively in RG would be shorter than that in LG.

This meta-analysis revealed that the intraoperative blood loss in RG was less than that in LG, and the number of lymph nodes dissected in RG was higher than that in LG. There are abundant blood vessels and lymphatic vessels in the perigastric tissue. The process of LG perigastric tissue separation and lymph node dissection is prone to haemorrhage, which may affect the operator's ability to identify the tissue structure and to view the operation field. Due to the advantages of the robotic, these issues have been resolved (–), such as: (1) jitter filtering, the robotic arm eliminates the natural tremor in the human hand and improves the stability of the operation; (2) High-definition three-dimensional images, 3D three-dimensional images magnify the surgical field by 10–15 times, revealing the small blood vessels and tissue structure around the stomach, making the blood vessels around the stomach more secure, and improving the accuracy of the procedure; (3) Robotic arms have seven degrees of freedom to simulate the mechanical wrist, which allows for greater flexibility of operation and the ability to work in confined spaces; (4) The operator controls the robotic arm individually, eliminating the problem of incompatibility between the mirror arm and the operator; (5) The operator adopts a sitting position that provides both physical comfort and improves the efficiency of his or her operation; (6) Remote control by the operator so to avoid direct contact with the patient; (7) Reconstruction of the digestive tract to achieve a full endoscopic anastomosis which is suitable for obesity, barrel chests, high esophageal cut planes, a small costal arch angle, and anterior and posterior abdominal walls. There are several advantages to total endoscopic in vivo anastomosis for patients with the same diameter and width. These attributes, without a doubt, improve surgical precision and stability, minimise mistake rates, and promote minimally invasive surgery.

A patient's prognosis and degree of surgical cure are affected by the number of lymph nodes dissected at the time of surgery for early gastric cancer. As a treatment for intermediate and advanced gastric cancer, D2 lymph node dissection remains the standard procedure. Nonetheless, it is difficult to dissect D2 lymph nodes in LG. The included studies (, , , , ) showed that more lymph nodes had been cleared in the RG group than in the LG group, while the remaining studies showed no significant differences between the two groups in terms of lymph node clearance (, , , , , 55). Across the included studies (–), the number of surgically cleared lymph nodes in RG ranged between 13.6 and 91.7, while all were able to reach the range of clearance of D2 lymph nodes. It has been revealed that RG can have therapeutic benefits that are comparable to LG and may even exceed them (for example in dissection, abdominal reduction, suturing etc).

We found that the RG group had a shorter first postoperative food intake period than the LG group. We found substantial discrepancies between Kim et al. () and Zhang et al. () among the independent literature examined. Possible reasons are (, ): (1) The robotic arm moves stably and flexibly during RG operation, helping to avoid overstretching and separation of tissues and accidental injury to blood vessels, thus causing less trauma to patients; (2) Adopting the concept of enhanced recovery surgery after perioperative management, Zhang et al. () reported earlier postoperative time to get out of bed, first gassing and eating time in the RG group compared to the LG group. As a result of the meta-analysis, however, the potential factor could not be the cause of the different postoperative hospital stay between the groups of RG and LG. A slight statistically significant difference was found between the two groups in terms of hospital stay, but the RG did appear to be preferred.

A meta-analysis of the data revealed that there was no difference in the rest of the data between the RG and LG group. Despite this, there is heterogeneity in first postoperative flatus time, postoperative complications, proximal incision margin distance, distal incision margin distance, tumor size, and 3-year survival rate. There may be a variety of reasons for this: (1) The operators included in the study may be in different stages of their RG development, and the indicators are heterogeneous. (2) The tumor size, location, and stage of included studies are different; (3) Preoperative management and surgical methods are also different, contributing to varying results. The findings of a high-quality non-randomized controlled trial, however, were also convincing when evaluating the short-term effects of surgery, as shown by Abraham et al. (56). After reviewing the high-quality literature, it was discovered that there was no significant difference between the two groups in terms of the number of lymph nodes dissected (WMD = 1.87, 95% CI = −1.24, 3.97, P > 0.05), and the rest of the results remained unchanged, indicating that systematic analysis results are relatively reliable.

This study has some limitations (1) the inclusion of the most recent literature and exclusion of studies with duplicate cases; (2) the inclusion of a relatively large number of studies, which increased the number of relevant cases; and (3) the systematic analysis of long-term survival information, such as the 3-year survival rate. Several limitations exist in this meta-analysis, including: (1) the included literature was retrospective, lacking high-quality randomized controlled trials, some of which had a small number of patients, which may have contributed to publication bias, and (2) the recurrence rate was not examined.

Conclusion

Based on our meta-analysis, RG appears to have superior therapeutic effects than traditional LG for treating gastric cancer and both are safe and practical. Its future application opportunities will improve as more experience is gathered. In the future, large-scale, multi-sampled multicenter randomised controlled studies will be required to increase the reliability of RG in clinical therapy.

Statements

Author contributions

SB: administrative support, provision of study materials or subjects, and manuscript writing. QS; MHA: administrative support, collection and assembly of data, and manuscript writing. YW; QS: provision of study materials or subjects, data analysis, and interpretation. MJ; LW; MA: collection and assembly of data, data analysis and interpretation, and manuscript writing. DW: conception and design, and final approval of the manuscript. All authors have read and approved the manuscript.

Funding

The author(s) declare that no funding was received from any government or private institution, organization, and any other entity.

Acknowledgments

The authors are thankful to Yangzhou University for providing the necessary facilities to carry our the meta-analysis. We are also thankful to Negenome Bio Solutions Pvt Ltd for the statistical analyses and for their constant support.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fsurg.2022.895976/full#supplementary-material.

References

  • 1.

    TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalA. Global cancer statistics, 2012. CA Cancer J Clin. (2015) 65(2):87–108. 10.3322/caac.21262

  • 2.

    ChenKWuDPanYCaiJQYanJFChenDWet alTotally laparoscopic gastrectomy using intracorporeally stapler or hand-sewn anastomosis for gastric cancer: a single-center experience of 478 consecutive cases and outcomes. World J Surg Oncol. (2016) 14:115. 10.1186/s12957-016-0868-7

  • 3.

    JunfengZYanSBoTYingxueHDongzhuZYongliangZet alRobotic gastrectomy versus laparoscopic gastrectomy for gastric cancer: comparison of surgical performance and short-term outcomes. Surg Endosc. (2014) 28(6):1779–87. 10.1007/s00464-013-3385-6

  • 4.

    EomBWYoonHMRyuKWLeeJHChoSJLeeJYet alComparison of surgical performance and short-term clinical outcomes between laparoscopic and robotic surgery in distal gastric cancer. Eur J Surg Oncol. (2012) 38(1):57–63. 10.1016/j.ejso.2011.09.006

  • 5.

    KangBHXuanYHurHAhnCWChoYKHanSU. Comparison of surgical outcomes between robotic and laparoscopic gastrectomy for gastric cancer: the learning curve of robotic surgery. J Gastric Cancer. (2012) 12(3):156–63. 10.5230/jgc.2012.12.3.156

  • 6.

    YoonHMKimYWLeeJHRyuKWEomBWParkJYet alRobot-assisted total gastrectomy is comparable with laparoscopically assisted total gastrectomy for early gastric cancer. Surg Endosc. (2012) 26(5):1377–81. 10.1007/s00464-011-2043-0

  • 7.

    UyamaIKanayaSIshidaYInabaKSudaKSatohS. Novel integrated robotic approach for suprapancreatic D2 nodal dissection for treating gastric cancer: technique and initial experience. World J Surg. (2012) 36(2):331–7. 10.1007/s00268-011-1352-8

  • 8.

    KimKMAnJYKimHICheongJHHyungWJNohSH. Major early complications following open, laparoscopic and robotic gastrectomy. Br J Surg. (2012) 99(12):1681–7. 10.1002/bjs.8924

  • 9.

    HuangKHLanYTFangWLChenJHLoSSHsiehMCet alInitial experience of robotic gastrectomy and comparison with open and laparoscopic gastrectomy for gastric cancer. J Gastrointest Surg. (2012) 16(7):1303–10. 10.1007/s11605-012-1874-x

  • 10.

    ZhangXLJiangZWZhaoK. [Comparative study on clinical efficacy of robot-assisted and laparoscopic gastrectomy for gastric cancer]. Zhonghua Wei Chang Wai Ke Za Zhi. (2012) 15(8):804–6. 10.3760/cma.j.issn.1671-0274.2012.08.016

  • 11.

    HyunMHLeeCHKwonYJChoSIJangYJKimDHet alRobot versus laparoscopic gastrectomy for cancer by an experienced surgeon: comparisons of surgery, complications, and surgical stress. Ann Surg Oncol. (2013) 20(4):1258–65. 10.1245/s10434-012-2679-6

  • 12.

    KimHIParkMSSongKJWooYHyungWJ. Rapid and safe learning of robotic gastrectomy for gastric cancer: multidimensional analysis in a comparison with laparoscopic gastrectomy. Eur J Surg Oncol. (2014) 40(10):1346–54. 10.1016/j.ejso.2013.09.011

  • 13.

    NoshiroHIkedaOUrataM. Robotically-enhanced surgical anatomy enables surgeons to perform distal gastrectomy for gastric cancer using electric cautery devices alone. Surg Endosc. (2014) 28(4):1180–7. 10.1007/s00464-013-3304-x

  • 14.

    HuangKHLanYTFangWLChenJHLoSSLiAFet alComparison of the operative outcomes and learning curves between laparoscopic and robotic gastrectomy for gastric cancer. PLoS One. (2014) 9(10):e111499. 10.1371/journal.pone.0111499

  • 15.

    SonTLeeJHKimYMKimHINohSHHyungWJ. Robotic spleen-preserving total gastrectomy for gastric cancer: comparison with conventional laparoscopic procedure. Surg Endosc. (2014) 28(9):2606–15. 10.1007/s00464-014-3511-0

  • 16.

    LiuJRuanHZhaoKWangGLiMJiangZ. [Comparative study on da vince robotic and laparoscopic radical gastrectomy for gastric cancer]. Zhonghua Wei Chang Wai Ke Za Zhi. (2014) 17(5):461–4. 10.3760/cma.j.issn.1671-0274.2014.05.013

  • 17.

    HanDSSuhYSAhnHSKongSHLeeHJKimWHet alComparison of surgical outcomes of robot-assisted and laparoscopy-assisted pylorus-preserving gastrectomy for gastric cancer: a propensity score matching analysis. Ann Surg Oncol. (2015) 22(7):2323–8. 10.1245/s10434-014-4204-6

  • 18.

    SeoHSShimJHJeonHMParkCHSongKY. Postoperative pancreatic fistula after robot distal gastrectomy. J Surg Res. (2015) 194(2):361–6. 10.1016/j.jss.2014.10.022

  • 19.

    ParkJYRyuKWReimDEomBWYoonHMRhoJYet alRobot-assisted gastrectomy for early gastric cancer: is it beneficial in viscerally obese patients compared to laparoscopic gastrectomy?World J Surg. (2015) 39(7):1789–97. 10.1007/s00268-015-2998-4

  • 20.

    LeeJKimYMWooYObamaKNohSHHyungWJ. Robotic distal subtotal gastrectomy with D2 lymphadenectomy for gastric cancer patients with high body mass index: comparison with conventional laparoscopic distal subtotal gastrectomy with D2 lymphadenectomy. Surg Endosc. (2015) 29(11):3251–60. 10.1007/s00464-015-4069-1

  • 21.

    SudaKManIMIshidaYKawamuraYSatohSUyamaI. Potential advantages of robotic radical gastrectomy for gastric adenocarcinoma in comparison with conventional laparoscopic approach: a single institutional retrospective comparative cohort study. Surg Endosc. (2015) 29(3):673–85. 10.1007/s00464-014-3718-0

  • 22.

    ShenWXiHWeiBCuiJBianSZhangKet alRobotic versus laparoscopic gastrectomy for gastric cancer: comparison of short-term surgical outcomes. Surg Endosc. (2016) 30(2):574–80. 10.1007/s00464-015-4241-7

  • 23.

    PengLBingLHongyiLBaoqingJ. Application of the Da vinci robot operation system in gastric cancer. J Clin Pathol. (2015) 35(06):1103–6. 10.3978/j.issn.2095-6959.2015.06.045

  • 24.

    CianchiFIndennitateGTralloriGOrtolaniMPaoliBMacriGet alRobotic vs laparoscopic distal gastrectomy with D2 lymphadenectomy for gastric cancer: a retrospective comparative mono-institutional study. BMC Surg. (2016) 16(1):65. 10.1186/s12893-016-0180-z

  • 25.

    KimHIHanSUYangHKKimYWLeeHJRyuKWet alMulticenter prospective comparative study of robotic versus laparoscopic gastrectomy for gastric adenocarcinoma. Ann Surg. (2016) 263(1):103–9. 10.1097/SLA.0000000000001249

  • 26.

    NakauchiMSudaKSusumuSKadoyaSInabaKIshidaYet alComparison of the long-term outcomes of robotic radical gastrectomy for gastric cancer and conventional laparoscopic approach: a single institutional retrospective cohort study. Surg Endosc. (2016) 30(12):5444–52. 10.1007/s00464-016-4904-z

  • 27.

    HongSSSonSYShinHJCuiLHHurHHanSU. Can robotic gastrectomy surpass laparoscopic gastrectomy by acquiring long-term experience? A propensity score analysis of a 7-year experience at a single institution. J Gastric Cancer. (2016) 16(4):240–6. 10.5230/jgc.2016.16.4.240

  • 28.

    KimYWReimDParkJYEomBWKookMCRyuKWet alRole of robot-assisted distal gastrectomy compared to laparoscopy-assisted distal gastrectomy in suprapancreatic nodal dissection for gastric cancer. Surg Endosc. (2016) 30(4):1547–52. 10.1007/s00464-015-4372-x

  • 29.

    XueYZhangBZhangJLiPLiuHJiaB. Evaluation of clinical short-term outcomes of da vinci robotic gastrectomy for advanced gastric cancer. J Abdom Surg. (2016) 29(1):8–12. 10.3969/j.issn.1003-5591.2016.01.003

  • 30.

    ParisiAReimDBorghiFNguyenNTQiFCorattiAet alMinimally invasive surgery for gastric cancer: a comparison between robotic, laparoscopic and open surgery. World J Gastroenterol. (2017) 23(13):2376–84. 10.3748/wjg.v23.i13.2376

  • 31.

    YangSYRohKHKimYNChoMLimSHSonTet alSurgical outcomes after open, laparoscopic, and robotic gastrectomy for gastric cancer. Ann Surg Oncol. (2017) 24(7):1770–7. 10.1245/s10434-017-5851-1

  • 32.

    SlimKNiniEForestierDKwiatkowskiFPanisYChipponiJ. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. (2003) 73(9):712–6. 10.1046/j.1445-2197.2003.02748.x

  • 33.

    GaitianLPengCLinXHongbinL. Da vinci robot and laparoscopic radical total stomach comparison of short-term efficacy of resection. J Laparosc Surg. (2017) 22(10):721–5. 10.3969/j.issn.1003-5591.2016.01.003

  • 34.

    daTSongyanLShidongHYuxuanLXiaohuiD. Short-term outcomes of robot-assisted versus laparoscopic distal gastrectomy for gastric cancer. J Chin People's Lib Army Med Coll. (2017) 38(12):1095–7. 10.3969/j.issn.2095-5227.2017.12.001

  • 35.

    ShidongHZilongHGuijunZYoujunWXiaoweiXYuxuanLet alComparison of short-term outcome of da vinci robotic-assistedand laparoscopic-assisted radical gastrectomy for gastric cancer. Chin J Clin Res. (2017) 30(06):721–4. 10.13429/j.cnki.cjcr.2017.06.001

  • 36.

    LanXXiHZhangKCuiJLiMChenL. [Comparison of complications following open, laparoscopic and robotic gastrectomy]. Zhonghua Wei Chang Wai Ke Za Zhi. (2017) 20(2):184–9. 10.3760/cma.j.issn.1671-0274.2017.02.014

  • 37.

    LiuHBWangWJLiHTHanXPSuLWeiDWet alRobotic versus conventional laparoscopic gastrectomy for gastric cancer: a retrospective cohort study. Int J Surg. (2018) 55:15–23. 10.1016/j.ijsu.2018.05.015

  • 38.

    LuJZhengHLLiPXieJWWangJBLinJXet alA propensity score-matched comparison of robotic versus laparoscopic gastrectomy for gastric cancer: oncological, cost, and surgical stress analysis. J Gastrointest Surg. (2018) 22(7):1152–62. 10.1007/s11605-018-3785-y

  • 39.

    ObamaKKimYMKangDRSonTKimHINohSHet alLong-term oncologic outcomes of robotic gastrectomy for gastric cancer compared with laparoscopic gastrectomy. Gastric Cancer. (2018) 21(2):285–95. 10.1007/s10120-017-0740-7

  • 40.

    ZhangKHuangXGaoYLiangWXiHCuiJet alRobot-Assisted versus laparoscopy-assisted proximal gastrectomy for early gastric cancer in the upper location: comparison of oncological outcomes, surgical stress, and nutritional Status. Cancer Control. (2018) 25(1):1073274818765999. 10.1177/1073274818765999

  • 41.

    LiZLiJLiBBaiBLiuYLianBet alRobotic versus laparoscopic gastrectomy with D2 lymph node dissection for advanced gastric cancer: a propensity score-matched analysis. Cancer Manag Res. (2018) 10:705–14. 10.2147/CMAR.S161007

  • 42.

    Song-yan SL-jLXing-bangNYuYHong-liangZXiao-huiD. Comparison of da vinci robotic surgery system versus laparoscopic D2 radical distal gastrectomy for gastric cancer. J Chin Pract Diagn Ther. (2018) 32(3):245–7. 10.13507/j.issn.1674-3474.2018.03.011

  • 43.

    WangWJLiHTYuJPSuLGuoCAChenPet alSeverity and incidence of complications assessed by the clavien-dindo classification following robotic and laparoscopic gastrectomy for advanced gastric cancer: a retrospective and propensity score-matched study. Surg Endosc. (2019) 33(10):3341–54. 10.1007/s00464-018-06624-7

  • 44.

    GaoYXiHQiaoZLiJZhangKXieTet alComparison of robotic- and laparoscopic-assisted gastrectomy in advanced gastric cancer: updated short- and long-term results. Surg Endosc. (2019) 33(2):528–34. 10.1007/s00464-018-6327-5

  • 45.

    AlhossainiRMAltamranAAChoMRohCKSeoWJChoiSet alLower rate of conversion using robotic-assisted surgery compared to laparoscopy in completion total gastrectomy for remnant gastric cancer. Surg Endosc. (2020) 34(2):847–52. 10.1007/s00464-019-06838-3

  • 46.

    YeSPShiJLiuDNJiangQGLeiXTangBet alRobotic- versus laparoscopic-assisted distal gastrectomy with D2 lymphadenectomy for advanced gastric cancer based on propensity score matching: short-term outcomes at a high-capacity center. Sci Rep. (2020) 10(1):6502. 10.1038/s41598-020-63616-1

  • 47.

    ShibasakiSSudaKNakauchiMNakamuraKKikuchiKInabaKet alNon-robotic minimally invasive gastrectomy as an independent risk factor for postoperative intra-abdominal infectious complications: a single-center, retrospective and propensity score-matched analysis. World J Gastroenterol. (2020) 26(11):1172–84. 10.3748/wjg.v26.i11.1172

  • 48.

    KongYCaoSLiuXLiZWangLLuCet alShort-Term clinical outcomes after laparoscopic and robotic gastrectomy for gastric cancer: a propensity score matching analysis. J Gastrointest Surg. (2020) 24(3):531–9. 10.1007/s11605-019-04158-4

  • 49.

    ShinHJSonSYWangBRohCKHurHHanSU. Long-term comparison of robotic and laparoscopic gastrectomy for gastric cancer: a propensity score-weighted analysis of 2084 consecutive patients. Ann Surg. (2021) 274(1):128–37. 10.1097/SLA.0000000000003845

  • 50.

    HikageMFujiyaKKamiyaSTanizawaYBandoENotsuAet alRobotic gastrectomy compared with laparoscopic gastrectomy for clinical stage I/II gastric cancer patients: a propensity score-matched analysis. World J Surg. (2021) 45(5):1483–94. 10.1007/s00268-020-05939-8

  • 51.

    LiZYLiuJJYuPWZhaoYLShiYLuoZYet alRobotic total gastrectomy for carcinoma in the remnant stomach: a comparison with laparoscopic total gastrectomy. Gastroenterol Rep. (2021) 9(6):583–8. 10.1093/gastro/goab021

  • 52.

    van BoxelGIRuurdaJPvan HillegersbergR. Robotic-assisted gastrectomy for gastric cancer: a European perspective. Gastric Cancer. (2019) 22(5):909–19. 10.1007/s10120-019-00979-z

  • 53.

    Jimenez-RodriguezRMDiaz-PavonJMde la Portilla de JuanFPrendes-SilleroEDussortHCPadilloJ. Learning curve for robotic-assisted laparoscopic rectal cancer surgery. Int J Colorectal Dis. (2013) 28(6):815–21. 10.1007/s00384-012-1620-6

  • 54.

    MegeDHainELakkisZMaggioriLProstALDJPanisY. Is trans-anal total mesorectal excision really safe and better than laparoscopic total mesorectal excision with a perineal approach first in patients with low rectal cancer? A learning curve with case-matched study in 68 patients. Colorectal Dis. (2018) 20(6):O143–51. 10.1111/codi.14238

  • 55.

    PuglieseRMaggioniDSansonnaFCostanziAFerrariGCDi LerniaSet alSubtotal gastrectomy with D2 dissection by minimally invasive surgery for distal adenocarcinoma of the stomach: results and 5-year survival. Surg Endosc. (2010) 24(10):2594–602. 10.1007/s00464-010-1014-1

  • 56.

    AbrahamNSByrneCJYoungJMSolomonMJ. Meta-analysis of well-designed nonrandomized comparative studies of surgical procedures is as good as randomized controlled trials. J Clin Epidemiol. (2010) 63(3):238–45. 10.1016/j.jclinepi.2009.04.005

Summary

Keywords

robotic, laparoscopic, gastrectomy, gastric cancer, meta-analysis

Citation

Baral S, Arawker MH, Sun Q, Jiang M, Wang L, Wang Y, Ali M and Wang D (2022) Robotic Versus Laparoscopic Gastrectomy for Gastric Cancer: A Mega Meta-Analysis. Front. Surg. 9:895976. doi: 10.3389/fsurg.2022.895976

Received

14 March 2022

Accepted

09 June 2022

Published

28 June 2022

Volume

9 - 2022

Edited by

Salman Yousuf Guraya, College of Medicine University of Sharjah, United Arab Emirates

Reviewed by

Airazat M. Kazaryan, Østfold Hospital, Norway Jacopo Andreuccetti, Civil Hospital of Brescia, Italy

Updates

Copyright

*Correspondence: Daorong Wang

Specialty section: This article was submitted to Surgical Oncology, a section of the journal Frontiers in Surgery

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics